Mark D. Roycik, Ph.D.
Affiliations: | 2010 | Florida State University, Tallahassee, FL, United States |
Area:
BiochemistryGoogle:
"Mark Roycik"Mean distance: (not calculated yet)
Parents
Sign in to add mentorQing-Xiang A. Sang | grad student | 2010 | Florida State | |
(Mercaptosulfonamides: Potential modulators of human mesenchymal stem cell behavior.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Bosco DB, Roycik MD, Jin Y, et al. (2017) A new synthetic matrix metalloproteinase inhibitor reduces human mesenchymal stem cell adipogenesis. Plos One. 12: e0172925 |
Hoyne G, Rudnicka C, Sang QX, et al. (2016) Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer. Bmc Cancer. 16: 151 |
Mu T, Liang W, Ju Y, et al. (2013) Efficient soluble expression of secreted matrix metalloproteinase 26 in Brevibacillus choshinensis. Protein Expression and Purification. 91: 125-33 |
Roycik MD, Myers JS, Newcomer RG, et al. (2013) Matrix metalloproteinase inhibition in atherosclerosis and stroke. Current Molecular Medicine. 13: 1299-313 |
Jin Y, Roycik MD, Bosco DB, et al. (2013) Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core. Journal of Medicinal Chemistry. 56: 4357-73 |
Roycik MD, Fang X, Sang QX. (2009) A fresh prospect of extracellular matrix hydrolytic enzymes and their substrates Current Pharmaceutical Design. 15: 1295-1308 |
Muroski ME, Roycik MD, Newcomer RG, et al. (2008) Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis Current Pharmaceutical Biotechnology. 9: 34-46 |
Lee S, Desai KK, Iczkowski KA, et al. (2006) Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate tumor. Cell Research. 16: 750-8 |